Breaking Down Shandong Buchang Pharmaceuticals Co., Ltd. Financial Health: Key Insights for Investors

Investors tracking Shandong Buchang Pharmaceuticals (603858.SS) will want to dig into a mixed but data-rich financial picture: Q1 2025 revenue rose to CNY 2,784.95 million (up 5.5% year-over-year) while nine-month revenue through Sep 30, 2025 totaled CNY 8,468.58 million (slightly below CNY 8,514.4 million a year earlier), TTM revenue stood at CNY 11,150.18 million with revenue per share TTM of CNY 10.39, and gross profit TTM reached CNY 6,625.87 million; profitability shows sharp quarterly improvement-Q1 net income was CNY 307.26 million versus CNY 114.02 million in Q1 2024 and nine-month net income rose to CNY 868.32 million-yet TTM net profit margin is only 0.02% and ROE is negative (-4.68%), while liquidity and cash generation remain solid with operating cash flow TTM of CNY 1,543.85 million, levered free cash flow TTM of CNY 1,856.40 million and total cash of CNY 2,140.23 million; valuation and capital structure show market cap CN¥18.24 billion, debt-to-equity near 41.14%, EV/Revenue 1.68 and EV/EBITDA 15.11, and growth levers include 214 new drugs under development, 68 independently patented varieties and positioning in a global TCM market projected to expand from about USD 250.38 billion (2024) toward USD 478.06 billion by 2033-read on for a detailed breakdown of revenue drivers, margins, risks and opportunities.

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) Revenue Analysis

Shandong Buchang Pharmaceuticals reported solid top-line performance in early 2025 with a mix of quarterly growth and slight year-to-date softness. Key headline figures highlight stability in trailing revenue and a healthy gross-profit base supporting margins and valuation metrics.

• Q1 2025 revenue: CNY 2,784.95 million (+5.5% vs Q1 2024: CNY 2,640.56 million)
• 9M 2025 revenue (to Sep 30, 2025): CNY 8,468.58 million (vs 9M 2024: CNY 8,514.40 million)
• TTM revenue (as of Mar 31, 2025): CNY 11,150.18 million
• Revenue per share (TTM): CNY 10.39
• Quarterly revenue growth: 5.5%
• Gross profit (TTM): CNY 6,625.87 million
• Enterprise value / Revenue: 1.68

Revenue dynamics show a recovery in the most recent quarter while the nine-month comparison reflects modest pressure-offset by a robust TTM gross profit that supports margins and valuation. For investor context and ownership flows, see Exploring Shandong Buchang Pharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) Profitability Metrics

• Q1 2025 net income: CNY 307.26 million (vs. CNY 114.02 million in Q1 2024)
• Nine months ended Sep 30, 2025 net income: CNY 868.32 million (vs. CNY 312.86 million in same period 2024)
• Operating margin (TTM as of Mar 31, 2025): 14.59%
• Return on assets (TTM): 2.56%
• Return on equity (TTM): -4.68%
• Net profit margin (TTM): 0.02%
• TTM EPS: CNY 0.00; quarterly earnings growth: 169.50%

• Interpretation: strong absolute profit growth (Q1 and 9M 2025) suggests improving operating results, supported by a healthy operating margin of 14.59%.
• However, the extremely low net profit margin (0.02%) and TTM EPS of CNY 0.00 indicate limited net earnings retained per revenue, while negative ROE (-4.68%) signals equity-level weakness-potentially due to non-operating charges, financing costs, or equity base changes.
• Investors should reconcile operating profitability with net-income drivers and capital structure impacts when assessing valuation and risk.

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) - Debt vs. Equity Structure

• Market capitalization: CN¥18.24 billion
• Debt-to-equity ratio: 41.14%
• Total debt-to-equity ratio: 38.08%
• Book value per share: CN¥9.90
• Price-to-book ratio: 1.67
• Enterprise value / EBITDA: 15.11

• Leverage profile: With a debt-to-equity around 41% and total D/E near 38%, the company uses debt but remains below high-leverage thresholds common in more cyclical industries.
• Valuation context: P/B of 1.67 indicates investors pay a modest premium to net assets; EV/EBITDA of 15.11 signals a valuation that is neither bargain-level nor extremely stretched for a mid-cap pharma firm.
• Balance-sheet resilience: Book value per share of CN¥9.90 provides a tangible net-asset floor for equity holders, while the market cap of CN¥18.24 billion shows investor confidence beyond book backing.
• Investor considerations: Monitor interest coverage and cash generation relative to EBITDA to assess whether current leverage remains sustainable if margins or growth slow.

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) - Liquidity and Solvency

Key liquidity and solvency metrics for Shandong Buchang Pharmaceuticals highlight a company generating strong operational cash while maintaining moderate short-term coverage and a prudent dividend policy.

• Current ratio: 1.14 - indicates the company has CNY 1.14 in current assets for every CNY 1.00 of current liabilities.
• Operating cash flow (TTM): CNY 1,543.85 million - robust cash generation from core operations over the trailing twelve months.
• Levered free cash flow (TTM): CNY 1,856.40 million - cash available after interest and debt obligations, supporting reinvestment and shareholder returns.
• Total cash (most recent quarter): CNY 2,140.23 million - provides a near-term liquidity buffer.
• Total cash per share: CNY 2.02 - useful for assessing per-share cash reserve relative to market price.
• Dividend yield: 2.36% with payout ratio: 31.06% - suggests a balanced distribution policy with room to sustain dividends from cash generation.

For further investor context and ownership trends, see: Exploring Shandong Buchang Pharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) - Valuation Analysis

Key valuation metrics for Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) highlight a mixed picture: the company is unprofitable on a trailing twelve months (TTM) basis while market valuation relative to revenue and EBITDA shows moderate investor expectations.

• TTM Price-to-Earnings (P/E): -32.52 - indicates negative earnings over the past twelve months.
• Price-to-Sales (TTM): CN¥1.64 - the market values each yuan of revenue at CN¥1.64.
• Enterprise Value / Revenue (EV/Revenue): 1.68 - the total firm valuation is 1.68x annual revenue.
• Enterprise Value / EBITDA (EV/EBITDA): 15.11 - suggests market compensation for operating cashflow is ~15x.
• Return on Equity (ROE TTM): -4.68% - shareholders have experienced negative return on equity.
• Return on Assets (ROA TTM): 2.56% - modest asset-level profitability.

For broader corporate context including history and ownership, see: Shandong Buchang Pharmaceuticals Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) - Risk Factors

Key financial indicators for Shandong Buchang Pharmaceuticals highlight multiple areas of investor concern. The following metrics (trailing twelve months, unless noted) show marginal profitability, challenged shareholder returns, and valuation considerations that warrant close monitoring.

• TTM net profit margin: 0.02% - virtually breakeven, indicating extremely thin earnings relative to revenue.
• Return on equity (ROE) TTM: -4.68% - negative returns to shareholders, signaling loss-making or equity erosion.
• Return on assets (ROA) TTM: 2.56% - modest efficiency in converting assets to operating profit.
• Debt-to-equity ratio: 41.14% - moderate leverage; debt levels are material but not excessive.
• Price-to-earnings (P/E) ratio: -32.52 - negative P/E reflecting TTM losses and complicating earnings-based valuation.
• Enterprise value / EBITDA: 15.11 - valuation multiple that suggests a mid-to-high market valuation relative to operating earnings.

Primary risk themes investors should weigh:

• Earnings volatility: With a 0.02% net margin and negative ROE, small operational setbacks could push the company into sustained losses.
• Valuation ambiguity: Negative P/E complicates equity valuation; EV/EBITDA at 15.11 requires confidence in EBITDA stability or growth.
• Leverage exposure: A 41.14% debt-to-equity ratio elevates refinancing and interest-rate risks, particularly if margins remain compressed.
• Operational efficiency constraints: ROA of 2.56% indicates limited asset leverage-improvements needed to drive returns without adding risk.
• Investor sentiment and liquidity: Negative profitability metrics may dampen investor appetite, pressuring share liquidity and cost of capital.

For broader context on shareholder composition, trading behavior, and investor catalysts, see: Exploring Shandong Buchang Pharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) - Growth Opportunities

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) is positioned to convert R&D intensity, intellectual property depth, and targeted commercial strategies into sustained growth. Key quantitative signals and strategic initiatives highlight multiple levers for revenue expansion and margin improvement.

• R&D pipeline scale: 214 new drugs under development, indicating a sizable pipeline that can replenish product sales and enter new therapeutic areas.
• Proprietary IP breadth: 68 varieties with independent patents, including 55 listed on the National Essential Medicine List and 158 on the Medicine List for National Basic Medical Insurance - underpinning pricing stability and reimbursement access.
• Commercial channel build-out: investment in dedicated sales channels, direct engagement with healthcare professionals, and strategic partnerships with medical institutions to improve market penetration and shorten conversion cycles.
• Product innovation strategy: combining traditional remedies with modern delivery forms to drive higher unit prices, improve adherence, and create exportable formulations for international markets.

Growth pathways implied by these metrics:

• Pipeline commercialization - multiple launches from 214 candidates can offset patent cliffs and broaden therapeutic reach.
• Reimbursement-driven volume - 158 varieties on the national insurance list enhance price resilience and patient access.
• Channel efficiency - dedicated sales teams and hospital partnerships aim to lift penetration in key provinces and specialty clinics.
• Premiumization - reformulating traditional Chinese medicines into modern delivery systems (e.g., sustained-release, injectables, transdermal) to capture higher margins and differentiated market positions.
• Export opportunity - leveraging validated modernized TCM formulations to enter overseas TCM and integrative medicine markets in Asia, Europe, and North America.

Where investors should watch next (operational milestones and market context):

• Regulatory milestones for high-value candidates from the 214-drug pipeline (clinical approvals, NRDL inclusion candidates).
• New partnerships with major hospitals and provincial distributors that expand sales reach and reduce per-unit acquisition cost.
• Progress in modern delivery format launches and corresponding pricing power evidence.
• International registration or pilot exports tied to modernization of core TCM products.

For deeper background on corporate history, ownership, and how the company generates revenue, see: Shandong Buchang Pharmaceuticals Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money